Clinical Validation Stage
Clinical Validation Stage helps the founder or programme team complete a focused intervention on clinical workflow, endpoints, ethics, evidence and partners. Within Specialist Sector Support, it turns a broad or uncertain area of the venture into a concrete Bertie work product that can be reviewed, improved and reused. The task is intentionally discrete: it should produce a specific artefact, decision, evidence item or risk signal rather than general learning notes.
Complete a focused intervention that advances Clinical Validation Stage. The objective is to remove ambiguity around clinical workflow, endpoints, ethics, evidence and partners, give the founder a decision-ready output, and make it clear whether the venture should progress, repeat the task with stronger evidence, escalate to expert support, or move into a linked stage.
Bertie or a programme manager assigns Clinical Validation Stage when the venture needs a decision-ready output for this group. Typical triggers include group-gate reviews, evidence gaps identified by the co-pilot or founder request.
venture sector; domain assumptions; relevant regulation or evidence standard; product maturity; sector buyer map; specific context for clinical workflow, endpoints, ethics, evidence and partners.
Establish the precise clinical problem, patient population, and care context the venture targets. The founder defines what successful clinical validation looks like for this specific intervention stage.
ObjectiveClarifying this scope establishes explicit boundaries for the venture's clinical claims and evaluation criteria. It prevents wasted expenditure on irrelevant trials by aligning validation goals directly with target market requirements.
What's expectedDeliver a clear one-page clinical scope document identifying the target condition, user persona, care setting, and primary clinical claims. This must explicitly detail the core hypothesis that clinical validation will test.
Open action arrow_forwardConsultant stress-test · 5 questions- 1.What specific clinical problem does your venture address, and why is the existing standard of care insufficient?
- 2.How did you determine that this specific patient cohort represents the most viable entry point for validation?
- 3.Why have you chosen these specific clinical claims rather than broader wellness or operational metrics?
- 4.What evidence proves that clinicians view this exact problem as a high-priority unaddressed need?
- 5.How does your defined clinical scope align with current NHS or private healthcare purchasing pathways?
- A data-room asset titled Clinical Validation Stage
- A clear task output, updated venture DNA and recommended next action
- It should update the venture DNA with specific evidence or decisions about clinical workflow, endpoints, ethics, evidence and partners, create a visible milestone in the founder journey, and generate one or more recommended next tasks
Bertie co-pilot applies sector-specific criteria, flags regulatory or evidence gaps, prepares expert review briefs, and connects the venture to specialist tasks. For this task, it should focus on clinical workflow, endpoints, ethics, evidence and partners, prompt the founder for missing inputs, draft or improve the output, flag weak assumptions, and record the result back into the relevant data-room section.
A mentor or evaluator can review the output at the group gate. Programme managers can require an advisor checkpoint before Bertie moves the venture forward.